Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Accumulated Expenses (2020 - 2023)

Candel Therapeutics' Accumulated Expenses history spans 4 years, with the latest figure at $3.4 million for Q3 2023.

  • For Q3 2023, Accumulated Expenses rose 22.07% year-over-year to $3.4 million; the TTM value through Sep 2023 reached $3.4 million, up 22.07%, while the annual FY2022 figure was $2.6 million, 26.29% up from the prior year.
  • Accumulated Expenses for Q3 2023 was $3.4 million at Candel Therapeutics, up from $2.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $3.8 million in Q2 2022 and bottomed at $1.1 million in Q2 2021.
  • The 4-year median for Accumulated Expenses is $2.1 million (2021), against an average of $2.3 million.
  • The largest annual shift saw Accumulated Expenses soared 243.08% in 2022 before it crashed 60.34% in 2023.
  • A 4-year view of Accumulated Expenses shows it stood at $1.2 million in 2020, then soared by 74.96% to $2.1 million in 2021, then rose by 26.29% to $2.6 million in 2022, then increased by 29.54% to $3.4 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Accumulated Expenses are $3.4 million (Q3 2023), $2.0 million (Q2 2023), and $1.4 million (Q1 2023).